MAPT and Alzheimer disease: However, some evidence indicates that plasma biomarker ratios such as Aβ42/40 and the ratio of phosphorylated to non-phosphorylated tau (p-tau ratio) may normalize for non-AD-related individual differences and provide more consistent performance in classifying amyloid status across groups16,28–30.